Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB0,00
PKN53,653,70,68
Msft-1,50
Nokia4,3264,3291,00
IBM1,23
Daimler AG40,00540,022,80
PFE0,10
05.08.2020 1:38:56
Indexy online
AD Index online
select
AD Index online
 

  • 04.08.2020
Abbott Labs (ABT, NY Consolidated)
Závěr k 4.8.2020 Změna (%) Změna (USD) Objem obchodů (ks)
99,93 -0,74 -0,75 2 730 577
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 05.08.2020
Popis společnosti
Obecné informace
Název společnostiAbbott Laboratories
TickerABT
Kmenové akcie:Ordinary Shares
RICABT
ISINUS0028241000
Poslední známé roční výsledky31.12.2019
Poslední známé čtvrtletní výsledky30.06.2020
Počet zaměstnanců k 31.12.2019 107 000
Akcie v oběhu k 30.06.20201 770 529 999
Počet akcionářů k 31.12.2019 38 990
MěnaUSD
Konstituent indexůS&P 500
Kontaktní informace
Ulice100 Abbott Park Rd
MěstoABBOTT PARK
PSČ60064-3500
ZeměUnited States
Kontatní osoba 
Funkce kontaktní osoby 
Telefon12 246 676 100

Business Summary: Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States. Its Diagnostic Products include a range of diagnostic systems and tests. Its Nutritional Products include a range of pediatric and adult nutritional products. Its Company's Vascular Products include a range of coronary, endovascular, vessel closure and structural heart devices for the treatment of vascular disease. The Company, through St. Jude Medical, Inc., also offers products, such as rhythm management products, electrophysiology products, heart failure related products, vascular products, structural heart products and neuromodulation products.
Financial Summary: BRIEF: For the six months ended 30 June 2020, Abbott Laboratories revenues decreased 3% to $15.05B. Net income before extraordinary items decreased 32% to $1.08B. Revenues reflect Other segment decrease of 95% to $30M, Established Pharmaceutical Products segment decrease of 2% to $2.06B, All other Countries segment decrease of 4% to $9.56B, United States segment decrease of 2% to $5.49B. Dividend per share increased from $0.64 to $0.72.
Odvětvová klasifikace
TRBC2012Medical Equipment, Supplies & Distribution - NEC
RBSS2004Pharmaceuticals - Diversified
MGINDUSTRYMedical Equipment & Supplies
MGSECTORHealthcare
NAICSElectromedical and Electrotherapeutic Apparatus Manufacturing
NAICSMedicinal and Botanical Manufacturing
NAICSInVitro Diagnostic Substance Manufacturing
NAICSPharmaceutical Preparation Manufacturing
NAICSSurgical and Medical Instrument Manufacturing
NAICSResearch and Development in the Physical, Engineering, and Life Sciences
SICPharmaceutical Preparations
SICElectromedical Equipment
SICMedicinals And Botanicals
SICDiagnostic Substances
SICPharmaceutical Preparations
SICSurgical And Medical Instruments
SICCommercial Physical Research



  • Poslední aktualizace: 05.08.2020
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Executive Chairman of the BoardMiles White6531.03.202001.01.1993
President, Chief Executive Officer, Chief Operating Officer, DirectorRobert Ford4631.03.202001.01.2014
Chief Financial Officer, Executive Vice President - FinanceRobert Funck5801.03.202001.01.2005
Executive Vice President, General Counsel, SecretaryHubert Allen54
Executive Vice President of Human ResourcesMary Moreland5301.01.2019
Executive Vice President - VenturesJohn Capek5801.06.201501.01.2006
Executive Vice President - Medical DevicesLisa Earnhardt5001.01.2019
Executive Vice President - Core DiagnosticsJohn Ginascol6101.01.2019
Executive Vice President - Established PharmaceuticalsAndrew Lane4901.01.2015
Executive Vice President - Nutritional ProductsDaniel Salvadori4101.01.2014